# BioAge Labs, Inc. (BIOA)

> Source: Nexqual · https://nexqual.com/BIOA · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, BioAge Labs, Inc. (BIOA), nexqual.com/BIOA" · informational, not investment advice.

**Price:** USD 5.35 (-1.29% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 5.42 · day 5.28–5.5 · 52w 5.04–25.96 · market cap $246M · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $10.4M, net income -$94.5M (-912.3% margin), free cash flow -$88.1M (SEC filings).
- Analysts: Buy (mean 2.10 on a 1–5 scale) (10 analysts), mean target USD 32.56 (range 8–73).
- Total return with dividends: 1Y +4.7% vs S&P 500 +18.1%; 5Y -74.5% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.63, revenue estimate $1.5M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2024 | FY2025 | FY2025 | TTM |
|---|---|---|---|---|
| Revenue | — | $0K | $9.0M | $10.4M |
| Operating income | -$48.4M | -$78.2M | -$92.8M | -$106M |
| Net income | -$63.9M | -$71.1M | -$80.6M | -$94.5M |
| EPS (diluted) | -$38.17 | -$6.63 | -$2.24 | — |
| Free cash flow | -$37.5M | -$51.9M | -$82.3M | -$88.1M |
| Operating margin | — | — | -1031.5% | -1026.3% |
| Net margin | — | — | -896.1% | -912.3% |
| Cash + short-term investments | $21.6M | $354M | $281M | — |
| Total debt | $14.2M | $8.5M | $2.6M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 23.7x · P/B 0.7x · FCF yield -35.87% · Earnings yield -38.47%

## Analysts
Consensus Buy (mean 2.10 on a 1–5 scale), 10 analysts; mean target USD 32.56 (low 8, high 73).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | UBS | Initiated | Neutral | $8 |
| 2026-09-09 | Roth Capital | Reiterated | Buy | $25 |
| 2026-09-08 | BTIG | Reiterated | Buy | $40 |
| 2026-08-06 | BTIG | Reiterated | Buy | $40 |
| 2026-08-03 | BTIG | Reiterated | Buy | $40 |
| 2026-07-31 | Needham | Target lowered | Buy | $50 → $35 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2024-09-23) |
|---|---|---|
| Total return | +4.7% | -74.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +4.7% | -48.5% |
| Volatility (annualized) | 132.4% | 144.5% |
| Max drawdown | -78.7% (Jul 2026→Oct 2026) | -86.3% (Oct 2024→Mar 2025) |

## Peers (Drug Manufacturers - Specialty & Generic)
SUPN (Supernus Pharmaceuticals, Inc.) USD 39.57 -5.81% · HCM (HUTCHMED (China) Limited) USD 13.94 +3.26% · LQDA (Liquidia Corporation) USD 34.78 +29.73% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.65 +2.98% · INDV (Indivior Pharmaceuticals, Inc.) USD 33.62 -5.08% · RGC (Regencell Bioscience Holdings L) USD 9.52 +16.24%

## More
Full page: https://nexqual.com/BIOA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt